Myasthenia Gravis Treatment Market Outlook 2025-2034: Key Trends, Growth Drivers, and Market Share

What industry-specific factors are fueling the growth of the myasthenia gravis treatment market?
The escalating occurrence of myasthenia gravis is likely to stimulate the expansion of the myasthenia gravis treatment market in the future. Defined as an autoimmune neuromuscular disease, myasthenia gravis is characterised by fatigue and skeletal muscle weakness affecting patients. The treatment for myasthenia gravis involves providing health care services and support to patients to counteract the disease. This significant increase in myasthenia gravis cases is bolstering revenue for the myasthenia gravis treatment market. To illustrate, data released in January 2022 by the National Organization for Rare Disorders, a non-profit association based in the US providing assistance for people with rare diseases, estimated a prevalence of 14-40 individuals per 100,000 with autoimmune myasthenia gravis in the US alone. Moreover, in April 2024, the American Journal of Managed Care, a peer-reviewed journal based in the US, reported an average of 1,800 myasthenia gravis (MG) diagnoses per year, resulting in an estimated annual incidence rate of 4.32 cases per 100,000 individuals and a rate of 2.46 cases per 100,000 person-years. Hence, the soaring prevalence of myasthenia gravis is fuelling the enlargement of the myasthenia gravis treatment market.

Get Your Myasthenia Gravis Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

What Is the projected market size and growth rate for the myasthenia gravis treatment market?
The market size for treating myasthenia gravis has seen substantial growth in the past years. The market is expected to increase from $1.55 billion in 2024 to $1.66 billion in 2025, amounting to a compound annual growth rate (CAGR) of 7.3%. Reasons for this growth include the development of cholinesterase inhibitors, improvements in thymectomy procedures, advances in immunosuppressive therapies, the introduction of plasma exchange and an increase in patient advocacy.

Expectations are high for a healthy expansion of the myasthenia gravis treatment market in the upcoming years, with projections pointing to a value of $2.26 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.0%. Factors contributing to the predicted growth during the forecasted period include advancements in biologics and monoclonal antibodies, genetic and precision medicine, newly developing immune modulators, neuroprotective tactics, and biosimilar medicines. The forecast period is also likely to witness the rise of several key trends such as digital therapeutics, joint research endeavors, patient-focused methods, application of real-world evidence, and extended safety monitoring.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

What new trends are reshaping the myasthenia gravis treatment market and its opportunities?
A prevailing trend in the myasthenia gravis treatment market is the focus on product innovations. Major players in this market are honing in on the development of novel solutions to maintain their market position. For example, in October 2023, Zilucoplan, a product of UCB Pharma, a pharmaceutical company based in Belgium, received approval from the US Food and Drug Administration (FDA). Zilucoplan, used to treat adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor (AChR) antibodies, presents a fresh approach to gMG management, a condition marked by muscle weakness due to an autoimmune reaction. Distinctively, the drug ZILBRYSQ is a self-administered, once-daily subcutaneous complement C5 inhibitor, offering a convenient option compared to the traditional intravenous treatments that were the typical method for managing gMG.

What major market segments define the scope and growth of the myasthenia gravis treatment market?
The myasthenia gravis treatment market covered in this report is segmented -

1) By Treatment: Medication, Surgery, Other Treatments
2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) By End-Use: Hospitals, Clinics, Other End-Uses

Subsegments:
1) By Medication: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Corticosteroids
2) By Surgery: Thymectomy
3) By Other Treatments: Plasmapheresis, Intravenous Immunoglobulin (IVIg), Supportive Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11980

Which region dominates the myasthenia gravis treatment market?
North America was the largest region in the myasthenia gravis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the myasthenia gravis treatment industry growth?
Major companies operating in the myasthenia gravis treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

What Is Covered In The Myasthenia Gravis Treatment Global Market Report?

• Market Size Forecast: Examine the myasthenia gravis treatment market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the myasthenia gravis treatment market for a structured understanding.
• Key Players Overview: Analyze major players in the myasthenia gravis treatment market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the myasthenia gravis treatment market.
• Segment Contributions: Evaluate how different segments drive overall growth in the myasthenia gravis treatment market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the myasthenia gravis treatment market.
• Industry Challenges: Identify potential risks and obstacles affecting the myasthenia gravis treatment market.
• Competitive Landscape: Review strategic developments in the myasthenia gravis treatment market, including expansions, agreements, and new product launches.

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.